Stock Analysis
InventionMed (WSE:INM) Second Quarter 2024 Results
Key Financial Results
- Net loss: zł1.38m (down from zł339.9k profit in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
InventionMed's share price is broadly unchanged from a week ago.
Risk Analysis
We should say that we've discovered 4 warning signs for InventionMed (3 are significant!) that you should be aware of before investing here.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About WSE:INM
InventionMed
Focuses on the development of medical simulators based on Virtual Realty technology for use in education in esthetic and clinical dermatology.
